# Observational lymphoma studies recruiting: 240 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 240 trials that are observational for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational lymphoma studies: 240 rows for $12, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 240
- Recruiting or not yet: 240
- Read on: November 19, 2026

## Trials

The 25 newest of 240, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941063 | Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction | Chinese PLA General Hospital | Observational | Recruiting | Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941063) |
| November 16, 2026 | NCT07937566 | Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma... | Fondazione Italiana Linfomi - ETS | Observational | Not yet recruiting | Mantle Cell Lymphoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937566) |
| October 26, 2026 | NCT07895927 | Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational Study | University Hospital, Strasbourg, France | Observational | Recruiting | Adult Burkitt Lymphoma, Chemotherapy-Related Toxicity, Overall and Progression-Free Survival | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895927) |
| October 22, 2026 | NCT07888530 | Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Hrain Biotechnology Co., Ltd. | Observational | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma (NHL) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888530) |
| October 20, 2026 | NCT07882732 | RPM Signals in Outpatient CAR T Therapy | Current Health | Observational | Not yet recruiting | Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, B-Cell Lymphoma, Chronic Lymphocytic... | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882732) |
| October 20, 2026 | NCT07882576 | A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma | AstraZeneca | Observational | Not yet recruiting | Lymphoma, B-Cell | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882576) |
| October 16, 2026 | NCT07878351 | Prospective ctDNA Testing in Large B-Cell Lymphoma | Peking University People's Hospital | Observational | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878351) |
| October 13, 2026 | NCT07869797 | Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer... | Mundipharma (China) Pharmaceutical Co. Ltd | Observational | Not yet recruiting | Cancer Pain | 378 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869797) |
| October 7, 2026 | NCT07862764 | A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell... | AbbVie | Observational | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862764) |
| September 22, 2026 | NCT07834931 | PMCF Study Fortilink-TC Ti | BAAT Medical Products B.V. | Observational | Recruiting | Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834931) |
| September 22, 2026 | NCT07834736 | PMCF Study Fortilink-TS Ti | BAAT Medical Products B.V. | Observational | Recruiting | Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834736) |
| September 10, 2026 | NCT07813585 | Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART Network | The Royal Wolverhampton Hospitals NHS Trust | Observational | Not yet recruiting | Lymphoma | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813585) |
| September 4, 2026 | NCT07804173 | Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas | Sohag University | Observational | Not yet recruiting | Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804173) |
| August 25, 2026 | NCT07785505 | Musculoskeletal Ultrasound in Patients With Hematologic Malignancies | Assiut University | Observational | Not yet recruiting | Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Musculoskeletal Diseases | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785505) |
| August 17, 2026 | NCT07767799 | Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice | Fondazione Italiana Linfomi - ETS | Observational | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma (NHL) | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767799) |
| August 13, 2026 | NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Observational | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763054) |
| August 6, 2026 | NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | Natera, Inc. | Observational | Recruiting | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750886) |
| July 27, 2026 | NCT07727083 | Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases | Sponsor not shown (see the record) | Observational | Recruiting | Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease... | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727083) |
| July 20, 2026 | NCT07714044 | Rutgers University Study of the Genetics of Blood Cancers | Rutgers, The State University of New Jersey | Observational | Recruiting | Blood Cancers, Blood Cancer, Leukemia, Lymphoma, Myeloma, Hematologic Cancer, Hematologic Malignancies, Hematologic... | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714044) |
| July 20, 2026 | NCT07713511 | INfections in Patients Treated With CAR-T | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Observational | Not yet recruiting | Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections, CAR-T Cell... | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713511) |
| July 17, 2026 | NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | Sponsor not shown (see the record) | Observational | Not yet recruiting | Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal... | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711327) |
| July 10, 2026 | NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | Shenzhen Third People's Hospital | Observational | Not yet recruiting | HIV (Human Immunodeficiency Virus), AIDS, Kaposi Sarcoma (KS), Lymphoma, AIDS-Related Malignancy, Lung Cancer in the... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696169) |
| July 10, 2026 | NCT07695896 | Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Observational | Not yet recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695896) |
| June 25, 2026 | NCT07669194 | Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Observational | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669194) |
| June 18, 2026 | NCT07657572 | A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of... | Ruijin Hospital | Observational | Not yet recruiting | PTCL, T Cell Lymphoma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657572) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 15 |
| Fondazione Italiana Linfomi - ETS | 11 |
| National Cancer Institute (NCI) | 11 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 7 |
| Memorial Sloan Kettering Cancer Center | 5 |
| Assistance Publique - Hôpitaux de Paris | 5 |
| Assiut University | 4 |
| Stanford University | 3 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 3 |
| Wake Forest University Health Sciences | 3 |
| Fudan University | 3 |
| Peking Union Medical College Hospital | 3 |
| Peking University First Hospital | 3 |
| [iOMEDICO AG](https://specstream.ai/data/clinical-trials/company/iomedico-ag) | 2 |
| International Extranodal Lymphoma Study Group (IELSG) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| University Health Network, Toronto | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| National Taiwan University Hospital | 2 |
| Mayo Clinic | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Peking University People's Hospital | 2 |
| Oncology Institute of Southern Switzerland | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Munich Leukemia Laboratory | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 65 |
| China | 49 |
| Italy | 30 |
| France | 13 |
| Germany | 11 |
| Spain | 10 |
| United Kingdom | 9 |
| Canada | 8 |
| Switzerland | 7 |
| South Korea | 5 |
| Denmark | 5 |
| Belgium | 4 |
| Austria | 4 |
| Argentina | 3 |
| Netherlands | 3 |
| Australia | 3 |
| Brazil | 3 |
| Taiwan | 3 |
| Puerto Rico | 3 |
| Egypt | 3 |
| Portugal | 2 |
| Japan | 2 |
| Sweden | 2 |
| Czechia | 2 |
| Greece | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [Patio cover companies in the United States](https://specstream.ai/data/businesses/patio-cover-companies/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
